Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOperating.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — interest income of $6.66M in Q1 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income increased by 275.8% year-over-year, from $1.77M to $6.66M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income has grown at a 88.3% compound annual growth rate (CAGR), from $2.05M to $13.66M.
- What does development and licensing of biopharmaceutical assets — interest income mean?
- This metric captures the interest earned on cash balances, short-term investments, and other interest-bearing assets held by the development and licensing segment. It reflects the segment's ability to generate passive returns from its liquidity position. This income contributes to the overall financial health and self-funding capability of the business unit.